ArticleScientific reports2026
Comparative in vitro cytotoxicity of free curcumin and a liposomal curcumin formulation on various human cancer cell lines.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nutraceuticals in Uro-Oncology: A Structured Expert Review and Precision-Oriented Framework.Nutrients · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phospholipids derived from plants are promising for drug delivery applications. This study aimed to develop liposomes from cost-effective, plant-derived soy lecithin to enhance the cytotoxicity of curcumin (CUR) against a panel of human cancer cells. The optimized curcumin-loaded liposomes (CUR-Liposomes) were characterized and exhibited a nanoscale size of 105.7 nm, and a high negative zeta potential of -49.9 mV. The key finding from the in vitro cytotoxicity assay was that CUR-liposomes demonstrated significantly enhanced anticancer activity compared to free CUR, as evidenced by lower half maximal inhibitory concentration (IC50) values across all tested cancer cell lines, including multidrug-resistant MCF-7 breast adenocarcinoma (MCF-7/ADR), colon (Caco-2), lung (A549), prostate (PC3), and pancreatic (PANC-1) cancer cells. Notably, this enhanced cytotoxicity was not observed in normal Vero cells, suggesting a favorable selectivity profile. These findings demonstrate that liposomal encapsulation using plant-derived lipids is a viable strategy to improve the therapeutic efficacy and potential selectivity of CUR for cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.